Sanara MedTech Inc.

Sanara MedTech Inc. reported a net income of $6,093 for the first half of 2026, a significant improvement from a net loss of $5.54 million in the prior year period. Total net revenue increased by 13.6% to $55.9 million for the six months ended June 30, 2026. The company's operating income also grew by 33.6% to $4.43 million for the half-year. This turnaround was aided by the discontinuation of the Tissue Health Plus (THP) segment, which previously incurred substantial losses, though the most recent quarter showed a loss from continuing operations.

Sanara MedTech Inc. reported its second quarter 2026 financial results, with net revenue increasing 9% to $28.1 million and gross profit growing 10% to $26.2 million. Despite revenue growth, the company posted a net loss from continuing operations of $0.4 million for the quarter, compared to net income in the prior year, primarily due to higher operating expenses and interest. Adjusted EBITDA saw a modest increase to $5.0 million. Management also highlighted the recently announced agreement for Sanara to be acquired by MIMEDX, which is expected to combine their surgical portfolios.

Sanara MedTech announced a transformational agreement to be acquired by MIMEDX, a leading provider in wound care, burn, and surgical sectors. This combination is expected to deepen distributor relationships and expand operating presence. Concurrently, Sanara reported Q2 2026 net revenue increased 9% to $28.1 million, with gross profit rising to $26.2 million. However, the company posted a net loss from continuing operations of $0.4 million for the quarter, compared to a net income in the prior year, while Adjusted EBITDA grew to $5.0 million.

Sanara MedTech Inc. filed an amendment to its Agreement and Plan of Merger with MiMedx Group, Inc., correcting previously reported termination fee amounts. The amendment clarifies that Sanara's termination fee is $9,660,336.00 and MiMedx's is $22,540,785.00. The original merger agreement, entered on July 29, 2026, involves Sanara becoming a wholly-owned subsidiary of MiMedx. Sanara shareholders will receive $33.00 in cash and 0.4735 shares of MiMedx common stock per share.

MiMedx Group, Inc. announced its definitive agreement to acquire Sanara MedTech Inc. in a cash and stock transaction valued at $35 per Sanara share, totaling approximately $350 million in enterprise value. The acquisition is expected to create a leading regenerative medicine company, significantly expand MiMedx's surgical footprint, and be immediately accretive to its financial profile. The combined entity anticipates over $20 million in run-rate cost synergies and expects 2027 total revenue to exceed $400 million with an Adjusted EBITDA margin over 20%.

Sanara MedTech Inc. has terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective June 2, 2026. This decision aligns with Sanara's new strategy to concentrate on soft tissue repair and bone fusion products for the surgical market. The company incurred no fees or penalties for the termination, though certain covenants like indemnification and confidentiality will remain active. Notably, Sanara's Chairman, Ronald T. Nixon, is the founder of Catalyst, which, along with its affiliates, holds more than 5% of Sanara's common stock.

Sanara MedTech Inc. reported a significant financial turnaround for the first quarter ended March 31, 2026, with net revenue increasing by 18.6% to $27.8 million and the company swinging to a net profit of $0.46 million, or $0.05 per basic share, compared to a net loss in the prior year. This improvement follows the discontinuation of the Tissue Health Plus (THP) segment in Q3 2025, which was substantially complete by year-end 2025. The company also reduced earnout liabilities to zero due to non-renewal of the Petito Services Agreement and the discontinuation of THP.

Sanara MedTech Inc. reported strong first-quarter 2026 financial results, with net revenue increasing 19% to $27.8 million and achieving GAAP net profitability of $0.04 per diluted share from continuing operations, compared to a net loss in the prior year. The company's strategic realignment to focus solely on the surgical market, coupled with sales team expansion, drove these results. Sanara MedTech reaffirmed its full-year 2026 net revenue guidance of $116 million to $121 million.

Sanara MedTech Inc. reported strong financial results for the first quarter ended March 31, 2026, with net revenue increasing 19% to $27.8 million. The company achieved GAAP net profitability from continuing operations of $0.4 million, or $0.04 per diluted share, a significant improvement from a net loss in the prior year. This performance reflects the company's sharpened focus on the surgical market and enhanced financial model. Sanara MedTech reaffirmed its full-year 2026 net revenue guidance of $116 million to $121 million, representing 13% to 17% growth.